May 14, 2014 [email protected]

Spirulina – Powder or Tabs???

spirulina green smoothie vitamix

 

Let’s face it, if you’re looking into buying Spirulina then you’ve probably already either came to terms with the “green” taste or maybe even acquired the taste.  Either way, you’ve started to shift your diet away from highly processed, sugar and chemical filled foods, which provide simple sugar spikes as well as inflammation, hormone imbalances and a countless number of other health issues still under research.  Instead your focus has turned to the fuels that will sustain energy, harness vitality and promote a healthy sense of ease (as opposed to DISease).

Simply put, Spirulina is composed of tiny, single-celled fresh-water micro algae which contain an impressive 60% protein content!  Spirulina intake has also been shown to reduce blood cholesterol and inflammation (Caused by say… extreme exercise ;)).  Working spirulina into your routine can also help remove toxins, acting as a safe daily cleanse.

So the only question left once you get to the store is whether to buy it in a powder form or the tabs.  We tested out a container of each so we could break down what we liked and didn’t like about each, and hopefully help you all decide which one is best for you!

mel and jon spirulina fuel run

 

 

Spirulina Tabs –>

The best this these have going for them is hands down their convenience.  They are easy to swallow, the intense spirulina flavour goes almost undetected, and they can easily be packaged to bring with you while travelling or on long runs.  The one downside to the tabs is you may feel like a bit of a pill popper, as the recommended daily dose is 4 tabs, 4 times a day.

 

 

 

Prairie naturals spirulina powderSpirulina Powder –>

This is about as pure and natural as you’ll find it, and with the increased surface area of the spirulina cells in this form, it can lead to faster and better absorption into your body.  We’ve been using this in two fashions, first being a tsp stirred into a small glass of water.  This is a bit harsh in the “flavour” category, but acts great as a morning boost of healthy energy.  The more common one for us was simply adding a scoop into a smoothie and blend it all together.  This is much more appealing to the palet.

 

 

Decision ==>  When it comes down to what spirulina has to offer the body, we sided with the convenience of the tabs!  Being able to toss a handfull in a container to bring running, hiking or even just camping acts as a clean and healthy source of fuel for us when it’s simply not feasible to be messing around mixing powders.

Thanks for reading – let us know your preference and favourite ways you include these in your diet!!

Ultra Mel and Jon

Read how Spirulina has become our secret for Fueling Early Morning Workouts!

, , , , , , ,

Comments (3)

  1. lorri

    You might want to read this. http://www.science20.com/australian_researchers_discover_potential_blue_green_algae_cause_treatment_of_motor_neuron_disease_mnd_als-121193 > I have been waiting for test results of BNAA and have yet to get them. I am holding off before using Spirulina. I think prudence is advised.

    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295368/
    References and Notes
    1. Prasad U, Kurland LK. Arrival of new diseases on Guam: lines of evidence suggesting the post-Spanish origins of ALS and Parkinson’s dementia. J Pac Hist. 1997;32(2):217–228. http://www.jstor.org/pss/25169338.
    2. Kurland LT, Mulder DW. Epidemiologic investigations of amyotrophic lateral sclerosis. I. Preliminary report on geographic distribution, with special reference to the Mariana Islands, including clinical and pathologic observations. Neurology. 1954;4(5):355–378. http://www.ncbi.nlm.nih.gov/pubmed/13185376. [PubMed]
    3. Rao SLN, et al. The isolation and characterization of β-N-oxalyl-ʟ-α,β-diaminopropionic acid: a neurotoxin from the seeds of Lathyrus sativus. Biochemistry 33432–436.436(1964. http://dx.doi.org/10.1021/bi00891a022 [PubMed]
    4. Bell EA. The discovery of BMAA, and examples of biomagnifications and protein incorporation involving other non-protein amino acids. Amyotroph Lateral Scler. 2009;10(suppl 2):21–25. http://www.ncbi.nlm.nih.gov/pubmed/19929727. [PubMed]
    5. Vega A, Bell EA. α-Amino-β-methylaminopropionic acid, a new amino acid from seeds of Cycas circinalis. Phytochemistry. 1967;6(5):759–762. http://dx.doi.org/10.1016/S0031-9422(00)86018-5.
    6. Bell EA, et al. In: Toxicity of Cycads: Implications for Neurodegenerative Diseases and Cancer, Fifth Cycad Conference 1967 (Whiting MG, ed.) New York, NY:Third World Medical Research Foundation: 1988. A neurotoxic amino acid in seeds of Cycas circinalis.
    7. Polsky FI, et al. Distribution and toxicity of α-amino-β-methylaminopropionic acid. Fed Proc. 1972;31(5):1473–1475. http://www.ncbi.nlm.nih.gov/pubmed/5056173. [PubMed]
    8. Seawright AA, et al. Selective degeneration of cerebellar cortical neurons caused by cycad neurotoxin, ʟ-β-methylaminoalanine (ʟ-BMAA), in rats. Neuropathol Appl Neurobiol. 1990;16(2):153–169. http://dx.doi.org/10.1111/j.1365-2990.1990.tb00944.x. [PubMed]
    9. Spencer PS, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. 1987;237(4814):517–522. http://dx.doi.org/10.1126/science.3603037. [PubMed]
    10. Duncan MW, et al. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology. 1990;40(5):767–772. http://www.ncbi.nlm.nih.gov/pubmed/2330104. [PubMed]
    11. Cox PA, Sacks OW. Cycad neurotoxins, consumption of flying foxes, and ALS-PDC disease in Guam. Neurology. 2002;58(6):956–959. http://www.ncbi.nlm.nih.gov/pubmed/11914415. [PubMed]
    12. Cox PA, et al. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci USA. 2003;100(23):13380–13383. http://dx.doi.org/10.1073/pnas.2235808100. [PMC free article] [PubMed]
    13. Banack SA, Cox PA. Biomagnification of cycad neurotoxins in flying foxes: implications for ALS-PDC in Guam. Neurology. 2003;61(3):387–389. http://dx.doi.org/10.1212/01.WNL.0000078320.18564.9F. [PubMed]
    14. Murch SJ, et al. Occurrence of β-methylamino-ʟ-alanine (BMAA) in ALS/PDC patients from Guam. Acta Neurol Scand. 2004;110(4):267–269. http://dx.doi.org/10.1111/j.1600-0404.2004.00320.x. [PubMed]
    15. Paerl HW, Huisman J. Blooms like it hot. Science. 2008;320(5872):57–58. http://dx.doi.org/10.1126/science.1155398. [PubMed]
    16. Cox PA, et al. Diverse taxa of cyanobacteria produce β-N-methylamino-ʟ-alanine, a neurotoxic amino acid. Proc Natl Acad Sci USA. 2005;102(14):5074–5078. http://dx.doi.org/10.1073/pnas.0501526102. [PMC free article] [PubMed]
    17. Pablo J, et al. Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease. Acta Neurol Scand. 2009;120(4):216–225. http://dx.doi.org/10.1111/j.1600-0404.2008.01150.x. [PubMed]
    18. Mash D, et al. Neurotoxic non-protein amino acid BMAA in brain from patients dying with ALS and Alzheimer’s disease [poster]. Presented at: American Academy of Neurology Annual Meeting, Chicago, IL, 17 Apr 2008. Neurology. 2008;70(suppl 1):A329. Available: http://www.abstracts2view.com/aan2008chicago/view.php?nu=AAN08L_P06.127 [accessed 1 Feb 2012].
    19. Xie X, et al. Tracking brain uptake and protein incorporation of cyanobacterial toxin BMAA [abstract]. Presented at: 22nd Annual Symposium on ALS/MND, Sydney, Australia, 1 Dec 2011. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/22nd_international_symposium_on_alsmnd/abstract_book_2011.html [accessed 1 Feb 2012].
    20. RILUTEK® (riluzole) Tablets. Bridgewater, NJ:Sanofi-Aventis U.S., LLC. 2008. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020599s011s012lbl.pdf [accessed 1 Feb 2012].
    21. Who Gets ALS? [website]. Washington, DC:ALS Association (revised Feb 2011). Available: http://www.alsa.org/about-als/who-gets-als.html [accessed 1 Feb 2012].
    22. Alzheimer’s Association. 2011 Alzheimer’s Disease Facts and Figures. Chicago, IL:Alzheimer’s Association. 2011. Available: http://www.alz.org/downloads/Facts_Figures_2011.pdf [accessed 1 Feb 2012].
    23. Parkinson’s Disease Backgrounder [website]. Bethesda, MD:National Institute of Neurological Disorders and Stroke (updated 18 Oct 2004). Available: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm [accessed 1 Feb 2012].
    24. Armon C. Sports and trauma in amyotrophic lateral sclerosis revisited. J Neurol Sci. 2007;262(1-2):45–53. http://dx.doi.org/10.1016/j.jns.2007.06.021. [PubMed]
    25. Wong PC, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995;14(6):1105–1116. http://dx.doi.org/10.1016/0896-6273(95)90259-7. [PubMed]
    26. Genetics of ALS [website]. Washington, DC:ALS Association (2010). Available: http://www.alsa.org/research/about-als-research/genetics-of-als.html [accessed 1 Feb 2012].
    27. Snyder LR, et al. Lack of cerebral BMAA in human cerebral cortex. Neurology 7215)1360–1361.1361(2009. http://dx.doi.org/10.1212/WNL.0b013e3181a0fed1 [PMC free article] [PubMed]
    28. Montine TJ, et al. Lack of β-methylamino-ʟ-alanine in brain from controls, AD, or Chamorros with PDC. Neurology. 2005;65(5):768–769. http://dx.doi.org/10.1212/01.wnl.0000174523.62022.52. [PubMed]
    29. Cox PA, et al. Response to article by Montine TJ, et al.: Lack of β-methylamino-ʟ-alanine in brain from controls, AD, or Chamorros with PDC. Neurology. 2005;65(5):768–769. http://dx.doi.org/10.1212/01.wnl.0000174523.62022.52. [PubMed]
    30. Montine TJ. Reply from the authors. Neurology. 2005;65(5):768–769. http://dx.doi.org/10.1212/01.wnl.0000174523.62022.52. [PubMed]
    31. Murch SJ, et al. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci USA. 2004;101(33):12228–12231. http://dx.doi.org/10.1073/pnas.0404926101. [PMC free article] [PubMed]
    32. Banack SA, et al. Distinguishing the cyanobacterial neurotoxin β-N-methylamino-ʟ-alanine (BMAA) from its structural isomer 2,4-diaminobutyric acid (2,4-DAB). Toxicon. 2010;56(6):868–879. http://dx.doi.org/10.1016/j.toxicon.2010.06.006. [PubMed]
    33. Banack SA, et al. Distinguishing the cyanobacterial neurotoxin β-N-methylamino-ʟ-alanine (BMAA) from other diamino acids. Toxicon. 2011;57(5):730–738. http://dx.doi.org/10.1016/j.toxicon.2011.02.005. [PubMed]
    34. Lee JW, et al. Editing-defective tRNA synthetase causes protein misfolding and neurodegeneration. Nature. 2006;443(7107):50–55. http://dx.doi.org/10.1038/nature05096. [PubMed]
    35. Rodgers KJ, Shiozawa N. Misincorporation of amino acid analogues into proteins by biosynthesis. Int J Biochem Cell Biol. 2008;40(8):1452–1466. http://dx.doi.org/10.1016/j.biocel.2008.01.009. [PubMed]
    36. Rodgers KJ, et al. Biosynthetic incorporation of oxidized amino acids into proteins and their cellular proteolysis. Free Rad Biol Med. 2002;32(8):766–775. http://dx.doi.org/10.1016/S0891-5849(02)00768-2. [PubMed]
    37. Chan SW, et al. L-DOPA is incorporated into brain proteins of patients treated for Parkinson’s disease, inducing toxicity in human neuroblastoma cells in vitro. Exp Neurol. http://dx.doi.org/10.1016/j.expneurol.2011.09.029 [online 1 Oct 2011]. [PubMed]
    38. Rodgers KJ, et al. Evidence for ʟ-dopa incorporation into cell proteins in patients treated with levodopa. J Neurochem. 2006;98(4):1061–1067. http://dx.doi.org/10.1111/j.1471-4159.2006.03941.x. [PubMed]
    39. Ozawa K, et al. Translational incorporation of ʟ-3,4-dihydroxyphenylalanine into proteins. FEBS J. 2005;272(12):3162–3171. http://dx.doi.org/10.1111/j.1742-4658.2005.04735.x. [PubMed]
    40. Rodgers KJ, Dunlop R. The cyanobacteria-derived neurotoxin BMAA can be incorporated into cell proteins and could thus be an environmental trigger for ALS and other neurological diseases associated with protein misfolding [abstract]. Presented at: 22nd Annual Symposium on ALS/MND, Sydney, Australia, 1 Dec 2011. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/22nd_international_symposium_on_alsmnd/abstract_book_2011.html [accessed 3 Feb 2012].
    41. Dunlop RA, Rodgers KJ. Proteins containing BMAA generate autofluorescent aggregates and induce cell death [poster]. Presented at: 22nd Annual Symposium on ALS/MND Sydney, Australia, 1 Dec 2011. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/22nd_international_symposium_on_alsmnd/abstract_book_2011.html [accessed 3 Feb 2012].
    42. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(suppl):S10–S17. http://dx.doi.org/10.1038/nm1066. [PubMed]
    43. Krammer C, et al. Prion-like propagation of cytosolic protein aggregates: insights from cell culture models. Prion. 2009;3(4):206–212. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807693/ [PMC free article] [PubMed]
    44. Igaz LM, et al. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121(2):726–738. http://dx.doi.org/10.1172/JCI44867. [PMC free article] [PubMed]
    45. MND Association. International Symposium on ALS/MND Abstract Books 2005–2009 [website]. Northampton, United Kingdom:Motor Neurone Disease Association. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/previous.html [accessed 3 Feb 2012].
    46. Rao SD, et al. BMAA selectively injures motor neurons via AMPA/kainate receptor activation. Exp Neurol. 2006;201(1):244–252. http://dx.doi.org/10.1016/j.expneurol.2006.04.017. [PubMed]
    47. Rush T, et al. Synergistic toxicity of the environmental neurotoxins methylmercury and [beta]-N-methylamino-ʟ-alanine. NeuroReport. http://dx.doi.org/10.1097/WNR.0b013e32834fe6d6 [online 25 Dec 2011]. [PubMed]
    48. Lobner D, et al. Synergistic toxicity of the environmental neurotoxins methylmercury and beta-N-methylamino-ʟ-alanine (BMAA) [abstract]. Presented at: 22nd Annual Symposium on ALS/MND, Sydney, Australia, 1 Dec 2011. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/22nd_international_symposium_on_alsmnd/abstract_book_2011.html [accessed 3 Feb 2012]. [PubMed]
    49. Chi L, et al. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience. 2007;144(3):991–1003. http://dx.doi.org/10.1016/j.neuroscience.2006.09.064. [PMC free article] [PubMed]
    50. Brand LE. In: The Everglades, Florida Bay, and Coral Reefs of the Florida Keys (Porter JW, Porter KG, eds). Boca Raton, FL:CRC Press: 2002. The transport of terrestrial nutrients to South Florida coastal waters.
    51. Brand LE, et al. Cyanobacterial blooms and the occurrence of the neurotoxin, beta-N-methylamino-ʟ-alanine (BMAA), in South Florida aquatic food webs. Harmful Algae. 2010;9(6):620–635. http://dx.doi.org/10.1016/j.hal.2010.05.002. [PMC free article] [PubMed]
    52. Brand LE, et al. Cyanobacteria blooms and the occurrence of the neurotoxin BMAA in Florida aquatic food webs [poster]. Presented at: 22nd Annual Symposium on ALS/MND, Sydney, Australia, 1 Dec 2011. Available: http://www.mndassociation.org/research/for_researchers/international_symposium/22nd_international_symposium_on_alsmnd/abstract_book_2011.html [accessed 3 Feb 2012].
    53. Dietrich DR, et al. Toxin mixture in cyanobacterial blooms—a critical comparison of reality with current procedures employed in human health risk assessment. Adv Exp Med Biol. 2008;619:885–912. http://www.ncbi.nlm.nih.gov/pubmed/18461795. [PubMed]
    54. Cox PA, et al. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph Lateral Scler. 2009;10(Suppl 2):109–117. http://dx.doi.org/10.3109/17482960903286066. [PubMed]
    55. Holtcamp W. Was Lou Gehrig’s ALS caused by tap water? Miller-McCune Magazine, Health section, online edition (5 Jan 2012). Available: http://www.miller-mccune.com/health/was-lou-gehrigs-als-caused-by-tap-water-38804/ [accessed 3 Feb 2012].
    56. Esterhuizen M, Downing TG. β-N-methylamino-ʟ-alanine (BMAA) in novel South African cyanobacterial isolates. Ecotoxicol Environ Saf. 2008;71(2):309–313. http://dx.doi.org/10.1016/j.ecoenv.2008.04.010. [PubMed]
    57. Caller TA, et al. A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms. Amyotroph Lateral Scler. 2009;10(suppl 2):101–108. http://dx.doi.org/10.3109/17482960903278485. [PubMed]
    58. Karlsson O, et al. Early hippocampal cell death, and late learning and memory deficits in rats exposed to the environmental toxin BMAA (β-N-methylamino-ʟ-alanine) during the neonatal period. Behav Brain Res. 2011;219(2):310–20. [PubMed]
    59. BMAA is a potent chelator of zinc, so if increasing zinc concentrations absorbs more of the free (unbound) BMAA, which leaves less available for misincorporation into proteins.
    60. Adeona Pharmaceuticals. Positive clinical study results reported by Adeona’s oral zinc for ALS collaborator [press release]. Ann Arbor, MI:Adeona Pharmaceuticals, Inc. (30 Nov 2011). Available: http://adeonapharma.investorroom.com/index.php?s=43&item=101 [accessed 3 Feb 2012].

    • Lorri,
      Thanks for sharing your views on this, and we definitely appreciated reading the article. As with many health foods/supplements/”diets”/training programs we’ve found there’s simply ALWAYS evidence on the pro and con side. To wait for a completely lifestyle thats passes all the western science “grades” and has unanimous support worldwide, might leave us in a bit of a paralysis by analysis predicament.

      One of the first well backed articles we came across supporting spirulina and leading us to research and then include it into our diets was this one: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907180/

      Not at all trying to go back and forth on a topic, we always encourage discussion! We will try to keep tabs on the research you have broughten up, however as long as we are seeing valuable benefits to our own health and performance, we’ll continue using it for now.

Leave a Reply

Your email address will not be published. Required fields are marked *

10 * Time limit is exhausted. Please reload CAPTCHA.

Contact us

Follow us on any of the following social media links! And if you ever need to get a hold of us, feel free! We'd love to chat:)